Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery☆

@inproceedings{Meyer2013ComparingTS,
  title={Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery☆},
  author={Joel Meyer and Stephanie A. Harris and Iman Satti and Ian Poulton and Hazel C Poyntz and Rachel Tanner and Rosalind Rowland and Kristin L Griffiths and Helen A Fletcher and Helen McShane},
  booktitle={Vaccine},
  year={2013}
}
BACKGROUND New vaccines to prevent tuberculosis are urgently needed. MVA85A is a novel viral vector TB vaccine candidate designed to boost BCG-induced immunity when delivered intradermally. To date, intramuscular delivery has not been evaluated. Skin and muscle have distinct anatomical and immunological properties which could impact upon vaccine-mediated cellular immunity. METHODS We conducted a randomised phase I trial comparing the safety and immunogenicity of 1×10(8)pfu MVA85A delivered… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 14 citations